Guus Scheefhals, MSc, was appointed Chief Executive Officer of Crossbeta Biosciences in April 2010. Since December 2018, he also has served as CEO of Crossbeta spin-out company DegenRx.
Previously, he worked at Avantium Pharma, beginning in October 2003 as Vice President Business Development Life Sciences. In 2005, he was promoted to Chief Business Officer and member of the Management Team and, in 2009, to Chief Operating Officer.
Prior to his career at Avantium, he gained vast experience in the pharmaceutical industry in several commercial positions. He was Business Development Manager at DSM Biologics from September 1999 to October 2003. Before that, he worked at the Division Pharmaceutical & Industrial R&D of Analytico and the Product Partnering Division of Fresenius. Scheefhals holds a Master's Degree in Pharmacy from the Utrecht University.